

PRODUCT MONOGRAPH

MUCOMYST*
(Acetylcysteine)

Solution for Injection or Inhalation

Mucolytic
Antidote for Acetaminophen Poisoning

WellSpring Pharmaceutical Canada Corp.
400 Iroquois Shore Road
Oakville ON
L6H 1M5

Date of Preparation
2002.01.29

Control # 075829

* Trademark

MUCOMYST

Acetylcysteine Injection

THERAPEUTIC CLASSIFICATION

Mucolytic
Antidote for Acetaminophen Poisoning

ACTION

The viscosity of pulmonary mucous secretions depends on the concentrations of mucoprotein and to a lesser extent, deoxyribonucleic acid (DNA). The latter increases with increasing purulence owing to cellular debris. The mucolytic action of acetylcysteine is related to the sulfhydryl group in the molecule. This group probably "opens" disulfide linkages in mucus, thereby lowering the viscosity. The mucolytic activity of MUCOMYST (acetylcysteine) is unaltered by the presence of DNA, and increases with increasing pH. Significant mucolysis occurs between pH 7 and 9.

Acetaminophen is rapidly absorbed from the upper gastrointestinal tract, with peak plasma levels occurring between 30 and 60 minutes after therapeutic doses and, usually within 4 hours following an overdose. The parent compound, which is non-toxic, is extensively metabolized in the liver to form principally the sulfate and glucuronide conjugates, which are also non-toxic and are rapidly excreted in the urine.

A small fraction of the ingested dose is metabolized in the liver by the cytochrome P-450 mixed function oxidase enzyme system to form a reactive, potentially toxic, intermediate metabolite, which preferentially conjugates with hepatic glutathione to form the non-toxic cysteine and mercapturic acid derivatives which are then excreted by the kidney.

Therapeutic doses of acetaminophen do not saturate the glucuronide and sulphate conjugation pathways and do not result in formation of sufficient reactive metabolite to deplete glutathione stores.

However, following ingestion of a large overdose (150 mg/kg or greater) the glucuronide and sulfate conjugation pathways are saturated resulting in a larger fraction of the drug being metabolized via the P-450 pathway. The increased formation of reactive metabolite may deplete the hepatic stores of glutathione with subsequent binding of the metabolite to protein molecules within the hepatocyte resulting in cellular necrosis. Acetylcysteine probably protects the liver by maintaining or restoring the glutathione levels, or by acting as an alternate substrate for conjugation with and thus detoxification of the reactive metabolite.

INDICATIONS AND CLINICAL USES

MUCOMYST (acetylcysteine) is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions, in such conditions as chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung); acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis); pulmonary complications of cystic fibrosis; post tracheostomy care; pulmonary complications associated with surgery; use during anesthesia; post-traumatic chest conditions; atelectasis due to mucous obstruction; diagnostic bronchial studies (bronchograms, bronchosprometry, and bronchial wedge catheterization).

MUCOMYST administered orally or intravenously is also indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen.

CONTRAINDICATIONS

MUCOMYST (acetylcysteine) is contraindicated in those patients who are sensitive to the drug or to any of the inactive ingredients. There are no contraindications to oral or intravenous administration of acetylcysteine in the treatment of acetaminophen overdose.

WARNINGS

After proper administration of acetylcysteine, an increased volume of liquefied bronchial secretions may occur. When cough is inadequate, the open airway must be maintained, by mechanical suction if necessary. When there is a large mechanical block due to foreign body or local accumulation, the airway should be cleared by endotracheal aspiration, with or without bronchoscopy.

Asthmatics under treatment with MUCOMYST (acetylcysteine) should be watched carefully. If bronchospasm progresses, this medication should be immediately discontinued.

Generalized urticaria has been observed rarely in patients receiving oral acetylcysteine for acetaminophen overdose. If this occurs and other allergic symptoms appear, treatment with acetylcysteine should be discontinued unless it is deemed essential and the allergic symptoms cannot be otherwise controlled.

If encephalopathy due to hepatic failure is evident, acetylcysteine treatment should be discontinued to avoid further administration of nitrogenous substances. There are no data indicating acetylcysteine adversely influences hepatic failure; however, this remains a theoretical possibility.

PRECAUTIONS

With the administration of MUCOMYST (acetylcysteine) as a mucolytic agent, the patient may initially notice a slight disagreeable odour, which soon becomes not noticeable. With a face mask, there may be a stickiness on the face after nebulization, which is easily removed by washing with water.

MUCOMYST is not compatible with rubber and metals, particularly iron, copper and nickel. Silicone and lacquered rubber and plastic are satisfactory for use with MUCOMYST.

Under certain conditions, a colour change may take place in the solution of acetylcysteine in the opened vial. The light purple colour is the result of a chemical reaction which does not significantly impair the safety or mucolytic efficacy of acetylcysteine.

Continued nebulization of an acetylcysteine solution with a dry gas will result in an increased concentration of the drug in the nebulizer, because of evaporation of the solvent. Extreme concentration may impede nebulization and efficient delivery of the drug. Dilution of the nebulizing solution with Sterile Water for Injection, U.S.P., as concentration occurs, will obviate this problem.

Occasionally, severe and persistent vomiting occurs as a symptom of acute acetaminophen overdose. Treatment with oral acetylcysteine may aggravate the vomiting. Patients at risk of gastric hemorrhage (e.g., esophageal varices, peptic ulcers, etc.) should be evaluated concerning the risk of upper gastrointestinal hemorrhage versus the risk of developing hepatic toxicity, and treatment with acetylcysteine given accordingly. Dilution of the acetylcysteine with cola drinks minimizes the propensity of oral acetylcysteine to aggravate vomiting.

Drug/Laboratory Interaction

Acetylcysteine may cause a false-positive reaction with reagent dipstick tests for urinary ketones.

ADVERSE REACTIONS

Adverse reactions have been included in order of frequency; stomatitis, nausea and rhinorrhea. Sensitivity and sensitization to MUCOMYST (acetylcysteine) have been reported very rarely. A few susceptible patients, particularly asthmatics (See WARNINGS), may experience varying degrees of bronchospasm associated with the administration of nebulized acetylcysteine. Most patients with bronchospasm are quickly relieved by the use of a bronchodilator given by nebulization.

Oral or intravenous administration of acetylcysteine, especially in the large doses needed to treat acetaminophen overdose, in order of frequency may result in: nausea, vomiting and other gastrointestinal symptoms. Hypersensitivity reactions following the intravenous administration of acetylcysteine have been reported. Symptoms include rashes, facial edema, urticaria, hypotension and bronchospasm.

DOSAGE AND ADMINISTRATION AS A MUCOLYTIC AGENT

MUCOMYST (acetylcysteine) is available in lacquered rubber stoppered glass vials containing 10 mL or 30 mL. The 20% solution may be diluted to a lesser concentration with either sterile normal saline or Sterile Water for Injection, US.P.

Nebulization - face mask, mouth piece, tracheostomy: When nebulized into a face mask, mouth piece, or tracheostomy, 1-10 mL of the 20% solution may be given every 2-6 hours; the recommended dose for most patients is 3-5 mL of the 20% solution 3 to 4 times daily.

Nebulization - tent, croupette: In special circumstances it may be necessary to nebulize into a tent or croupette, and this method of use must be individualized to take into account the available equipment and the patient's particular needs. This form of administration requires very large volumes of the solution, occasionally as much as 300 mL during a single treatment period. If a tent or croupette must be used, the recommended dose is the volume of solution that will maintain a very heavy mist in the tent or croupette for the desired period. Administration for intermittent or continuous prolonged periods, including overnight, may be desirable.

Direct Instillation: When used by direct instillation, 1-2 mL of a 10 to 20% solution may be given as often as every hour.

When used for the routine nursing care of patients with tracheostomy, 1 to 2 mL of a 10 to 20% solution may be given every 1 to 4 hours by instillation into the tracheostomy.

Acetylcysteine may be introduced directly into a particular segment of the bronchopulmonary tree by inserting (under local anesthesia and direct vision) a small plastic catheter into the trachea. Two to 5 mL of the 20% solution may then be instilled by means of a syringe connected to the catheter.

Acetylcysteine may also be given through a percutaneous intratracheal catheter. One to 2 mL of the 20% solution every 1 to 4 hours may be given by a syringe attached to the catheter.

Diagnostic Bronchograms: For diagnostic bronchial studies, 2 or 3 administrations of 1 to 2 mL of the 20% solution should be given by nebulization or by instillation intratracheally, prior to the procedure.

Administration of Aerosol

Materials: MUCOMYST (acetylcysteine) may be administered using conventional nebulizers made of plastic or glass. Certain materials used in nebulization equipment react with acetylcysteine. The most reactive of these are certain metals (notably iron and copper), and rubber. Where materials may come into contact with acetylcysteine solution, parts made of the following acceptable materials should be used: glass, plastic, aluminum, anodized aluminum, chromed metal, tantalum, sterling silver, or stainless steel. Silver may become tarnished after exposure, but this is not harmful to the drug action or the patient.

Nebulizing Gases - Compressed tank gas (air) or an air compressor should be used to provide pressure for nebulizing the solution. Oxygen may also be used but should be used with usual caution in patients with severe respiratory disease and CO₂ retention.

Apparatus - MUCOMYST is usually administered as fine nebulae for its local effect, and the nebulizer used should be capable of providing optimal quantities of a suitable range of particle sizes.

The selection of apparatus for nebulization depends upon the desired particle size and rate of administration. Commercially available nebulizers will produce nebulae of acetylcysteine satisfactory for retention in the respiratory tract. Most of the nebulizers tested will supply a high proportion of the drug solution as particles of less than 10 microns in diameter. It has been shown that particle sizes up to 10 microns should be satisfactorily retained in the respiratory tract.

Units that nebulized acetylcysteine with a satisfactory efficiency were the Maxi-Myst Nebulizer (Mead Johnson Laboratories, Evansville, Indiana), Mist-O₂-Gette ET-I-T (Mist O₂ Gen Equipment Co., 2711 Adeline Street, Oakland, Calif.), De Vilbiss 42 (The De Vilbiss Co., Somerset, Pa.) and Vaponefrin Standard Plastic Nebulizer (Vaponefrin Co., Division U.S. Vitamin & Pharmaceutical Corp., 800 Second Avenue, New York, N.Y.). Other units tested performed with equivalent or lesser efficiency of nebulization.

Hand bulbs may be used but are not recommended for routine use for nebulizing MUCOMYST because their output is generally too small. Some hand-operated nebulizers deliver particles that are larger than optimum for inhalation therapy.

Heated (hot pot) Nebulizer - MUCOMYST SHOULD NOT BE PLACED DIRECTLY INTO THE CHAMBER OF A HEATED (HOT POT) NEBULIZER. A heated nebulizer may be part of the nebulization assembly to provide a warm saturated atmosphere if the MUCOMYST aerosol is introduced by means of a separate unheated nebulizer. Usual precautions for administration of warm saturated nebulae should be observed.

The nebulized solution may be breathed directly from the nebulizer. Nebulizers may also be attached to plastic face masks, plastic face tents, plastic mouthpieces, conventional plastic oxygen tents, or head tents. Suitable nebulizers may also be fitted for use with the various intermittent positive pressure breathing (IPPB) machines.

The nebulizing equipment should be cleaned immediately after use; the residues may occlude the fine orifices or corrode metal parts.

Prolonged Nebulization - When three-fourths of the initial volume of acetylcysteine solution has been nebulized, a quantity of Sterile Water for Injection, U.S.P. (approximately equal to the volume of solution remaining) should be added to the nebulizer. This obviates any concentration of the agent in the residual solvent remaining after prolonged nebulization.

Storage of Opened Vials - If only a portion of the solution in the vial is used, the remainder should be stored in a refrigerator and used within 96 hours to minimize contamination.

Compatibility

The physical and chemical compatibility of acetylcysteine solutions with other drugs commonly administered by nebulization, direct instillation, or topical application, has been studied.

Acetylcysteine should not be mixed with all antibiotics. For example, the antibiotics tetracycline hydrochloride, oxytetracycline hydrochloride and erythromycin lactobionate were found to be incompatible when mixed in the same solution. These agents may be administered from separate solutions if administration of these agents is desirable.

COMPATIBILITY* TESTS OF ACETYLCYSTEINE

Product and/or Agent(s)	Manufacturer (Trademark)	Compatibility Rating	Ratio Tested**	
			Acetyl-cysteine	Product or Agent
ANESTHETIC, GAS				
Halothane U.S.P.	Wyeth-Ayerst (Halothane)	Compatible	20%	Infinite
Nitrous Oxide U.S.P.	Nat'l Cylinder Gas Co.	Compatible	20%	Infinite
ANESTHETIC, LOCAL				
Cocaine HCl	Merck Frosst	Compatible	10%	5%
Lidocaine HCl	Astra Zeneca (Xylocaine HCl)	Compatible	10%	2%
Tetracaine HCl	Sanofi-Synthalabo (Pontocaine HCl)	Compatible	10%	1%
ANTIBACTERIALS				
Neomycin Sulfate	Pharmacia & Upjohn (Mycifradin Sulfate)	Compatible	10%	100 mg/ml
Streptomycin Sulf.	Merck Frosst	Compatible	10%	200 mg/ml
Penicillin G Potas. (mix & use at once)	Eli Lilly	Compatible	10%	100,000 U/ml
Bacitracin (mix & use at once)	Pharmacia & Upjohn	Compatible	10%	5,000 U/ml
Polymyxin B Sulf.	Burroughs Wellcome (Aerosporin)	Compatible	10%	50,000 U/ml
Methicillin Sodium	Bristol-Myers Squibb (Staphcillin)	Compatible	10%	500 mg/ml
Novobiocin Sodium	Pharmacia & Upjohn (Albamycin)	Compatible	10%	25 mg/ml
Dihydrostreptomycin Sulfate	Pharmacia & Upjohn	Compatible	10%	50 mg/ml
Kanamycin Sulfate	Bristol-Myers Squibb (Kantrex)	Compatible	17%	85 mg/ml
Chloramphenicol Sodium Succinate	Parke-Davis (Chloromycetin)	Compatible	20%	20 mg/ml
Oleandomycin Phosp. (mix and use at once)	Roerig	Compatible	10%	25 mg/ml
Chlortetracycline HCl	Wyeth-Ayerst (Aueomycin HCL)	Incompatible	10%	12.5 mg/ml
Erythromycin Lactobionate	Abbott (Erythrocin)	Incompatible	10%	15 mg/ml
Oxytetracycline HCl	Pfizer (Terramycin HCl)	Incompatible	10%	12.5 mg/ml
Tetracycline HCl	Wyeth-Ayerst (Achromycin)	Incompatible	10%	12.5 mg/ml
Sodium Cephalothin	Eli Lilly (Keflin)	Compatible	10%	110 mg/ml
BRONCHODILATORS				
Isoproterenol HCl	--	Compatible	3.0%	0.5%
Isoproterenol HCl	--	Compatible	10%	0.05%
Isoproterenol HCl	--	Compatible	20%	0.05%
Isoproterenol HCl	Sanofi-Synthalabo (Isuprel 1%)	Compatible	13.3%	0.33%
			(2 parts)	(1 part)
Epinephrine HCl	Parke-Davis (Adrenalin HCl 1:100)	Compatible	13.3%	0.33%
			(2 parts)	(1 part)
Bronkospray	Breon	Compatible	13.3%	
			(2 parts)	(1 part)
Aerolone Compound	Eli Lilly	Compatible	13.3%	
			(2 parts)	(1 part)

COMPATIBILITY* TESTS OF ACETYLCYSTEINE

Product and/or Agent(s)	Manufacturer (Trademark)	Compatibility Rating	Radio Tested *	
			Acetyl-cysteine	Product or Agent
CONTRAST MEDIA				
Propylidone Susp.	Glaxo (Dionosil)	Compatible	10%	25%(W/V)
Iodized Oil U.S.P.	Fougera(Lipiodol)	Incompatible	20%/20 mL	40%/10 ml
DECONGESTANTS				
Phenylephrine HCl	--	Compatible	3.0%	0.25%
Phenylephrine HCl	Synofi-Synthalabo (Neo-Synephrine)	Compatible	13.3% (2 parts)	0.16% (1 part)
DETERGENTS				
Alevaire	Synofi-Synthalabo	Compatible	13.3% (2 parts)	(1 part)
Tergemist	Abbott	Compatible	13.3% (2 parts)	(1 part)
ENZYMES				
Pancreatic Dornase (mix & use at once)	Merck Frosst (Dornavac)	Compatible	16.7%	8,000 U/ml
Chymotrypsin	Armour	Incompatible	5%	400 /ml
Trypsin	Armour	Incompatible	5%	400 /ml
SOLVENTS				
Propylene Glycol		Compatible	3%	10%
Alcohol		Compatible	12%	10-20%
STEROIDS				
Prednisolone 21 Phosphate	Merck Frosst (Hydeltrasol)	Compatible	16.7%	3.3 mg/ml
Dexamethasone 21- Phosphate	Merck Frosst (Decadron Phosphate)	Compatible	16%	0.8 mg/ml
OTHER AGENTS				
Hydrogen Peroxide		Incompatible	(All ratios)	

*The rating, **compatible**, means that there was no visible physical change in the admixture and that there was no predicted chemical incompatibility. All of the mixtures have been tested for short-term chemical compatibility by assaying for the concentration of acetylcysteine after mixing.

The rating, **incompatible**, is based on the formation of a precipitate, a change in colour, clarity, or odour, or other physical-chemical alteration.

**Entries are final concentrations. Values in parentheses relate volumes of MUCOMYST solutions to volumes of test solutions.

The supplying of these data should not be interpreted as a recommendation for combining acetylcysteine with other drugs. The Table is not presented as positive assurance that no incompatibility will be present, since these data are based only on short-term compatibility studies. Manufacturers of drug products may change formulations. This could alter compatibilities. These data are intended to serve only as a guide for predicting compounding problems.

If it is deemed advisable to prepare an admixture it should be administered as soon as possible after preparation. Do not store unused mixtures.

AS AN ANTIDOTE FOR ACETAMINOPHEN POISONING

In the case of an overdosage of acetaminophen, MUCOMYST (acetylcysteine) should be administered immediately if 24 hours or less have elapsed from the reported time of ingestion. To be effective in protecting against severe liver damage, therapy with MUCOMYST must be started within 10 hours of acetaminophen ingestion. There is some evidence of progressively diminished efficacy thereafter, possibly lasting up to 24 hours.

It should be borne in mind that after a toxic dose of acetaminophen, the patient may appear relatively well initially and may even continue normal activities for a day or two before the onset of hepatic failure.

The following procedure is recommended:

1. The stomach should be emptied promptly by lavage or by inducing emesis with syrup of ipecac. Syrup of ipecac should be given in a dose of 15 to 30 mL for children and 30 to 45 mL for adults accompanied by drinking copious quantities of water. The dose should be repeated if emesis does not occur in 20 minutes.

2. In the case of a mixed drug overdose, activated charcoal may be indicated. However, if activated charcoal has been administered, perform gastric lavage before administering oral acetylcysteine treatment. Activated charcoal will absorb acetylcysteine, and reduce its effectiveness.

3. Draw blood for acetaminophen plasma assay and for baseline SGOT, SGPT, bilirubin, prothrombin time, creatinine, BUN, blood sugar and electrolytes. The acetaminophen assay provides a reliable prognostic indication of potential hepatotoxicity and serves as a basis for determining the need for continuing with the maintenance doses of acetylcysteine treatment. (See section on acetaminophen assays - interpretation and methodology). The laboratory measurements are used to monitor hepatic and renal function and electrolyte and fluid balance.

4. Administer the loading dose of acetylcysteine as outlined in Tables I or II according to route of administration employed.

5. For information regarding oral and intravenous maintenance doses, See Tables I and II.

6. If the patient vomits the oral loading dose or any oral maintenance dose within one hour of administration repeat that dose.

7. If the patient is unable to retain the orally administered acetylcysteine, the antidote may be administered by duodenal intubation or by the intravenous route.

8. Repeat SGOT, SGPT, bilirubin, prothrombin time, creatinine, BUN, blood sugar and electrolytes daily if acetaminophen plasma level is in the potentially toxic range as discussed below.

PREPARATION OF MUCOMYST SOLUTION FOR ORAL ADMINISTRATION

Oral administration requires dilution of the 20% solution with cola drinks, or other soft drinks, to a final concentration of 5% (See Table I). If administered via gastric tube or Miller-Abbott tube, water may be used as the diluent. The dilutions should be freshly prepared and utilized within one hour. Remaining undiluted solutions in opened vials can be stored in the refrigerator up to 96 hours.

PREPARATION OF MUCOMYST FOR INTRAVENOUS SOLUTIONS

MUCOMYST (acetylcysteine) may be used for intravenous administration following acetaminophen overdose, according to Dosage Guidelines in Table II. Dilutions recommended should be prepared with 5% Dextrose and Water as appropriate.

MUCOMYST (acetylcysteine) for intravenous use should be considered as a single dose container. Solutions recommended under each column in Table II should be freshly prepared and used only over times stated.

ACETAMINOPHEN ASSAYS

INTERPRETATION AND METHODOLOGY - The acute ingestion of acetaminophen in quantities of 150 mg/kg or greater may result in hepatic toxicity. However, the reported history of the quantity of a drug ingested as an overdose is often inaccurate and is not a reliable guide to therapy of the overdose. **THEREFORE, PLASMA OR SERUM ACETAMINOPHEN CONCENTRATIONS, DETERMINED AS EARLY AS POSSIBLE, BUT NO SOONER THAN FOUR HOURS FOLLOWING AN ACUTE OVERDOSE, ARE ESSENTIAL IN ASSESSING THE POTENTIAL RISK OF HEPATOTOXICITY. (DO NOT WAIT FOR ASSAY RESULTS TOO BEGIN ACETYLCYSTEINE TREATMENT).**

Interpretation of Acetaminophen Assays:

1. When results of the plasma acetaminophen assay are available, refer to nomogram (Figure 1) to determine if plasma concentration is in the potentially toxic range. Values above the solid line connecting 200 $\mu\text{g}/\text{mL}$ at 4 hours with 50 $\mu\text{g}/\text{mL}$ at 12 hours are associated with a possibility of hepatic toxicity, if an antidote is not administered.
2. If the plasma level is above the broken line, continue with maintenance doses of acetylcysteine. It is better to err on the safe side and thus the broken line is plotted 25% below the solid line which defines possible toxicity.
3. If the plasma level is below the broken line described above, there is minimal risk of hepatic toxicity and acetylcysteine treatment can be discontinued.

Acetaminophen Assay Methodology - Assay procedures most suitable for determining acetaminophen concentrations utilize high pressure liquid chromatography (HPLC) or gas liquid chromatography (GLC). The assay should measure only parent acetaminophen and not conjugated. The assay procedures listed below fulfill this requirement:

Selected techniques (non-inclusive)

HPLC:

1. Blair, D., and Rumack, B.H., **Clin. Chem.** **23** (4) : 743-745 (April) 1977.
2. Howie, D., Adriaenssens, P.I., and Prescott, L.F.: **Journ. Pharm. and Pharmacol.:** **29**(4) : 235-237 (April) 1977. GLC:
3. Prescott, L.F., **Journ. Pharm. and Pharmacol.:** **23** (10) : 807-808 (Oct.) 1971.
Colorimetric:
4. Glynn, J.P., and Kendal, S.E.: **The Lancet** **1**, 1147-1148 (May 17) 1975.

SUPPORTIVE TREATMENT FOR ACETAMINOPHEN OVERDOSE

1. Maintain fluid and electrolyte balance based on clinical evaluation of state of hydration and serum electrolytes.
2. Treat as necessary for hypoglycemia.
3. Administer Vitamin K if prothrombin time ratio exceeds 1.5 or fresh frozen plasma if the prothrombin time ratio exceeds 3.0.
4. Diuretics and forced diuresis should be avoided.

Hemodialysis or peritoneal dialysis have not been found helpful.

TABLE 1**DOSAGE GUIDE AND PREPARATION FOR ORAL ADMINISTRATION**

Doses in relation to body weight are:

DOSE OF MUCOMYST

Body Weight (Kg)	Grams MUCOMYST	mLs of 20% MUCOMYST	mLs of Diluent	Total mLs of 5% Solution
LOADING DOSE**				
100-110	15	75	225	300
90-100	14	70	210	280
80-90	13	65	195	260
70-80	11	55	165	220
60-70	10	50	150	200
50-60	8	40	120	160
40-50	7	35	105	140
30-40	6	30	90	120
20-30	4	20	60	80

MAINTENANCE DOSE**

100-110	7.5	37	113	150
90-100	7	35	105	140
80-90	6.5	33	97	130
70-80	5.5	28	82	110
60-70	5	25	75	100
50-60	4	20	60	80
40-50	3.5	18	52	70
30-40	3	15	45	60
20-30	2	10	30	40

Four hours after the loading dose, administer the first maintenance dose (70 mg of acetylcysteine per kg of body weight). The maintenance dose is then repeated at 4 hour intervals for a total of 17 doses unless the acetaminophen assay reveals a non-toxic level as discussed above.

** If patient weighs less than 20 kg, usually patients younger than 6 years, calculate the dose of MUCOMYST (acetylcysteine). Each mL of 20% MUCOMYST contains 200 mg of acetylcysteine. The loading dose is 140 mg per kilogram of body weight. The maintenance dose is 70 mg/kg. Three (3) mL of diluent are added to each mL of 20% MUCOMYST. Do not decrease the proportion of diluent. Increased gastrointestinal irritation is associated with increased concentrations of MUCOMYST (acetylcysteine).

TABLE II
DOSAGE GUIDE AND PREPARATION FOR INTRAVENOUS
ADMINISTRATION

INFUSION	INITIAL INFUSION (in 5% dextrose over 15 minutes)		2nd INFUSION (in 500 mL litre 5% dextrose dextrose over 4 hours) 16 hours}	3rd (in 1 5% over
BODY WEIGHT (Kg)	MUCOMYST MUCOMYST (mL)	5% DEXTROSE (mL)	MUCOMYST (mL)	(mL)
10-15	11.25	40	3.75	7.50
15-20	15.00	50	5.00	10.00
20-25	18.75	75	6.25	12.50
25-30	22.50	75	7.50	15.00
30-40	30.00	100	10.00	20.00
40-50	37.50	200	12.50	25.00
50-60	45.00	200	15.00	30.00
60-70	52.50	200	17.50	35.00
70-80	60.00	200	20.00	40.00
80-90	67.50	200	22.50	45.00
90-100	75.00	200	25.00	50.00
100-110	82.50	200	27.50	55.00


The volumes and rates of infusion for children suggested in table II, must be adjusted according to the medical circumstances. Restrictions in the volumes of parental fluids administered and the state of hydration and serum electrolytes for each patient must be monitored closely.

Estimating Potential for Hepatotoxicity -

A nomogram, Figure 1, has been developed to estimate the probability that plasma acetaminophen levels in relation to intervals post-ingestion will result in hepatotoxicity.

FIGURE 1*

FIGURE 1*
PLASMA OR SERUM ACETAMINOPHEN
CONCENTRATION VS. TIME POST ACETAMINOPHEN INGESTION



* Adapted from Rumack and Matthews, *Pediatrics* 55: 871-876, 1975.


PHARMACEUTICAL INFORMATION

Proper Name:Acetylcysteine

Trade Name:MUCOMYST

Chemical Name:N-acetyl-L-cysteine

Structural Formula:



Molecular Weight:163.2

Description:A white crystalline powder which melts at 104°-110°C and has a very slight odour.

Composition:Each mL contains 200 mg acetylcysteine, 0.5 mg disodium edetate in water for injection. Sodium hydroxide is used to adjust the pH.

Storage:Store unopened vials at room temperature. Under certain conditions, a colour change may take place in the solution of acetylcysteine in the opened vial. The light purple colour is the result of a chemical reaction which does not significantly impair the safety or mucolytic efficacy of acetylcysteine.

MUCOMYST Solution for Inhalation

Store opened vials in refrigerator and use within 96 hours

If an admixture is prepared use immediately (see DOSAGE AND ADMINISTRATION: AS A MUCOLYTIC AGENT).

Reconstituted Solutions:MUCOMYST Solution for Oral Administration

- Dilute the 20% solution with cola drinks or other soft drinks to a concentration of 5% (see DOSAGE AND ADMINISTRATION PREPARATION OF MUCOMYST SOLUTION FOR ORAL ADMINISTRATION). The dilutions should be freshly prepared and utilized within one hour. Remaining undiluted solutions in opened vials can be stored in refrigerator up to 96 hours.

MUCOMYST Solution for Intravenous Infusion

- Dilutions should be prepared with 5% Dextrose and water. Discard unused portion. Solutions should be freshly prepared and used only over times stated. (see DOSAGE AND ADMINISTRATION - PREPARATION OF SOLUTION FOR INTRAVENOUS SOLUTIONS)

MUCOMYST is not compatible with rubber and metals, particularly iron, copper and nickel.

AVAILABILITY

MUCOMYST (acetylcysteine) is supplied as a sterile 20% solution, in rubber stoppered glass vials of 10 mL and 30 mL. It also contains Edtate Disodium and sodium Hydroxide.

PHARMACOLOGY

MUCOMYST (acetylcysteine) is highly efficacious in preventing lethality from acute acetaminophen overdosage in CF-1 mice, even when therapy is delayed 4½ hours after dosing with acetaminophen. This time frame is especially noteworthy, since unprotected mice become debilitated by 1½ hours, have liver involvement by 3½ hours and die as early as 4 to 5 hours post-overdose.

The protective effect of acetylcysteine in preventing lethality was accompanied by marked hepatoprotection, which was closely reflected by the serum transaminase profile (SGPT) when the antidote was administered early. However, SGPT levels were found to be poor prognostic indicators of survival in late acetylcysteine administration.

Parallel comparisons with reference compounds indicate that acetylcysteine is more efficacious than cysteamine in both overall survival rate and effectiveness on late administration (4½ hours after acetaminophen dosing). Similar studies with methionine indicate that both acetylcysteine and methionine show high efficacy, but that methionine produces a bell-shaped rather than a linear dose response pattern on late administration, i.e., the higher as well as the lower doses resulted in lower survival rates than the mid-range doses. A highly lethal acetaminophen challenge dose was used (1500 mg/Kg) resulting in a 7% survival rate in the untreated mice.

The effects of delayed administration after a less severe challenge (1200 mg/Kg) were examined. The survival rate in the untreated mice was 70%. Treatment was initiated 9 hours after overdosing. When acetylcysteine was administered at this time which coincided with peak acetaminophen-induced liver insult, slight protection rather than exacerbation of toxicity occurred. In this experiment the reference compound, methionine, showed a similar pattern. Cysteamine, in contrast, showed a tendency to worsen the overall condition of animals if treatment was instituted as early as 4½ hours after dosing with 1200 mg/Kg of acetaminophen.

Safety assessment of acutely administered acetylcysteine to normal CF-1 mice indicates that it is extremely well tolerated by both oral and intravenous routes.

TOXICOLOGY

Acute toxicity studies conducted in various animal species show that MUCOMYST (acetylcysteine) is innocuous. The oral LD 50 of acetylcysteine was greater than 1000 mg/Kg in dogs, greater than 3000 mg/Kg in mice and 6000 mg/Kg in rats. With parenteral administration (intravenous or intraperitoneal) to the same three species and to guinea pigs, the LD₅₀ ranged between 700 mg/Kg for the dog and 2650 mg/Kg for the rat.

Gross and microscopic studies performed at autopsy on rats and dogs, treated with very large oral doses of acetylcysteine for 8 weeks, revealed no pathologic abnormalities in either species attributable to the administration of the agent. During administration of the test doses, growth and body weights of the animals were not deleteriously affected. Hemograms and liver function studies revealed no abnormalities attributable to the drug.

Histologic studies were done in guinea pigs exposed to aerosol sprays of 3% and 18% solutions of acetylcysteine for 15 minutes daily for 8 weeks. The histologic sections of the lungs, trachea, bronchi and larynx of these animals were not different from those of the control group exposed to normal saline. The mortality and morbidity rates in the two groups were not significantly different.

Other groups of guinea pigs were exposed to nebulization of the 3% and 18% solutions of acetylcysteine daily for three weeks, rested for two weeks, and then re-exposed for three days. These studies revealed no evidence of sensitization.

Dogs, rabbits and rats were exposed to a chamber atmosphere produced by 30 second nebulization of a 20% solution of acetylcysteine; these test animals remained in the atmosphere for an additional 15 minutes. Exposure was done twice daily for 35 consecutive days. Other groups of rabbits, rats and guinea pigs were exposed to a chamber atmosphere produced by continuous nebulization of a 20% solution of acetylcysteine for 1 hour a day 5 days a week for 12 weeks. No clinical or histopathological changes were found that could be attributed to acetylcysteine.

No evidence of local irritation was observed with acetylcysteine injected intracutaneously in guinea pigs. Ciliary activity in excised rat trachea was not inhibited by topical application of acetylcysteine.

Toxicology mechanism studies indicated that the antidotal profile of acetylcysteine is not related to facilitated plasma or urinary clearance of acetaminophen or acetaminophen metabolites, nor to cleavage of covalent bonds or significant tissue re-distribution of acetaminophen or its metabolites. Acetylcysteine antidotal therapy was associated with increased mercapturate conjugate in the urine, suggesting that acetylcysteine, like endogenous glutathione, may be serving as a substrate for the detoxification of the reactive metabolite of acetaminophen.